Lannett Kicks Off Insulin Glargine Trial
Firm Eyes 2023 Filing And 2024 Launch For US Interchangeable Biosimilar Lantus Rival
Lannett has delivered on its promise of kicking off a pivotal clinical trial for its proposed interchangeable biosimilar rival to Lantus by the end of March, as it eyes a 2023 filing and 2024 launch in the US for the insulin glargine product on which it has partnered with HEC.
